Breaks Categories: Stock Spotlights

FridaySep 01, 2023 12:17 pm

BioMedNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Secures Patent Protection in ‘Some of the Most Important Markets in the World’

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, recently received a patent from the China National Intellectual Property Administration. “The granted patent broadly covers the use of the company’s drug candidate REQORSA(R) immunogene therapy in combination with PD-1 antibodies, such as Keytruda(R), to treat cancers. The REQORSA gene therapy in combination with Keytruda is the subject of the company’s ongoing Acclaim-2 clinical trial for the treatment of non-small cell lung cancer (‘NSCLC’). In this trial, the company is enrolling and treating patients with advanced, metastatic NSCLC whose disease progressed…

Continue Reading

FridayAug 25, 2023 2:14 pm

BioMedNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Is Fast on the Trail to Target IL-17

BiondVax (NASDAQ: BVXV), a biotechnology company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, in-licensed the next antibody from the Max Planck Institute – a NanoAb designed to target interleukin-17 (“IL-17”) for the treatment of psoriasis, HS and other important indications. “BiondVax is now fast on the trail of developing what could be a very promising drug. Autoimmune diseases are often chronic and require patients to take drugs for life, with annual sales for current anti-interleukin-17 monoclonal antibodies totaling about $7.5 billion. With their NanoAbs, BiondVax aims to generate a…

Continue Reading

MondayAug 07, 2023 1:05 pm

BioMedNewsBreaks – CNS Pharmaceuticals Inc.’s (NASDAQ: CNSP) Berubicin Distinguished with Unique Capabilities

CNS Pharmaceuticals (NASDAQ: CNSP), a Texas-based cancer drug innovator, is focused on advancing its potentially pivotal clinical trial to track the effectiveness of drug candidate Berubicin in treating glioblastoma (“GBM”) brain cancers. Berubicin has already produced one patient with over 15 years of GBM survival. “Berubicin distinguishes itself by being virtually unique in its status as a cancer-fighting anthracycline that crosses the blood-brain barrier to attack central nervous system tumors directly. Berubicin also distinguished itself by presenting statistically significant improvement in nearly half of the two dozen patients evaluated in a phase I trial in 2006, including one patient whose…

Continue Reading

FridayJul 28, 2023 12:41 pm

BioMedNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Leveraging Unique NanoAb Pipeline to Target Large, Growing Markets

BiondVax (NASDAQ: BVXV) is an innovative biotechnology company focused on developing, manufacturing and commercializing potential blockbuster immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases. The company is developing a pipeline of unique nanosized antibody (“NanoAb”) therapies addressing diseases underserved by current treatments with large, growing markets, including dermatological conditions such as psoriasis. “BiondVax is initially targeting IL-17 [the human immune system cytokine, which is implicated in several diseases] for the treatment of psoriasis, where the market for therapeutics is expected to reach $44 billion by 2031,” reads a recent article. “The company’s plan for the IL-17 nanobody…

Continue Reading

MondayJul 24, 2023 3:17 pm

BioMedNewsBreaks – BiondVax Pharmaceuticals Ltd.’s (NASDAQ: BVXV) CDMO Services Designed to Meet Needs of Pharmaceutical, Biotechnology Companies of All Sizes

BiondVax (NASDAQ: BVXV) is a biotechnology company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases. The company recently showcased its boutique end-to-end contract development and manufacturing organization (“CDMO”) services and expertise at a leading conference for International Life Science and HealthTech industries, the Biomed Conference, in Tel Aviv. “These CDMO services will allow BiondVax to partner with pharmaceutical companies to provide contract-based drug development and manufacturing services, leveraging its Good Manufacturing Practices (‘GMP’) biologics manufacturing facility in Jerusalem… The company’s CDMO services are designed to meet the needs of pharmaceutical…

Continue Reading

MondayJul 17, 2023 2:15 pm

BioMedNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Positioned to Expand Its Clinical Pipeline

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, recently announced that its research collaborators presented positive preclinical data for the reexpression of the NPRL2 gene. “The collaborators conducted the studies using the ONCOPREX(R) Nanoparticle Delivery System to deliver the NPRL2 gene to KRAS/STK11 mutant, anti-PD1 resistant, human NSCLC metastases in humanized mouse models, presenting the data at the 2023 American Association of Cancer Research (‘AACR’) annual meeting, held in April,” reads a recent article. “According to Genprex President, Chairman and CEO Rodney Varner, the use of ONCOPREX(R) to deliver…

Continue Reading

MondayJul 03, 2023 11:31 am

BioMedNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Well Positioned to Move next NanoAb Candidates into Clinical Application

BiondVax (NASDAQ: BVXV), a biotechnology company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, recently signed an exclusive worldwide license agreement to develop and commercialize VHH antibodies (“NanoAbs”) that target Interleukin-17 (“IL-17”). “The license agreement is part of a broad-based collaboration with the Max Planck Society and the University Medical Center Göttingen (‘UMG’). The NanoAbs will be targeted toward the treatment of several relevant indications, including, but not limited to, psoriasis and psoriatic arthritis. BiondVax’s collaboration with the Max Planck Institute for Multidisciplinary Sciences and UMG, both based in Germany,…

Continue Reading

FridayJun 16, 2023 2:26 pm

BioMedNewsBreaks – Genprex Inc.’s (NASDAQ: GNPX) Flagship Candidate Could Potentially Reshape NSCLC Landscape

Genprex (NASDAQ: GNPX) is conducting its Phase 1/2 Acclaim-1 clinical trial evaluating the safety and efficacy of combining REQORSA(R), the company’s innovative drug candidate, in combination with Tagrisso(R) in patients with advanced EGFR mutant non-small cell lung cancer (“NSCLC”) who have experienced disease progression after previous treatments. “REQORSA Immunogene Therapy represents a potentially groundbreaking experimental drug that harnesses the power of genetic medicine to combat NSCLC,” a recent article explains. “During the Phase 1 portion of the clinical trial, the primary emphasis is on evaluating the safety of the treatment. However, the findings also have revealed promising efficacy results. One…

Continue Reading

MondayJun 12, 2023 1:42 pm

BioMedNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Leveraging Big Pharma Competencies to Bring Innovative Therapies to Market Quicker, at Lower Cost

BiondVax (NASDAQ: BVXV), a biotechnology company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, recently published Q1 2023 financial results and provided a business update. “The Q1 2023 results were in line with analysts’ expectations. R&D expenses increased about $800,000 from Q1 2022, which BiondVax attributed to the initiation and ramp-up of R&D activities for its innovative nanosized VHH antibody (‘NanoAb’) platform. In particular, the company finalized a preclinical proof-of-concept study of its inhaled anti-COVID NanoAb drug, reporting in January that the therapy virtually eliminated the SARS-CoV-2 virus in the…

Continue Reading

WednesdayJun 07, 2023 2:58 pm

BioMedNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Eyes Broad-Based Application Potential of ONCOPREX(R) Nanoparticle Delivery System

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing treatments for patients with cancer and diabetes, recently announced that its research collaborators presented positive preclinical data for the NRPL2 tumor suppressor gene. “The studies used Genprex’s non-viral ONCOPREX(R) Nanoparticle Delivery System in KRAS/STK11 mutant anti-PD1 resistant metastatic human non-small cell lung cancer (‘NSCLC’) humanized mouse models. Genprex’s ONCOPREX(R) Nanoparticle Delivery System is a novel non-vital approach utilizing lipid nanoparticles to deliver tumor suppressor genes that have been deleted during the course of cancer development. The platform allows for intravenous delivery of various tumor suppressor genes, and potentially…

Continue Reading